Last reviewed · How we verify
Viaskin Peanut 250µg
Viaskin Peanut 250µg is an epicutaneous immunotherapy that works by gradually increasing tolerance to peanut allergens.
Viaskin Peanut 250µg is an epicutaneous immunotherapy that works by gradually increasing tolerance to peanut allergens. Used for Treatment of peanut allergy.
At a glance
| Generic name | Viaskin Peanut 250µg |
|---|---|
| Sponsor | DBV Technologies |
| Drug class | Epicutaneous immunotherapy |
| Modality | Small molecule |
| Therapeutic area | Allergy |
| Phase | Phase 3 |
Mechanism of action
It does this by delivering small amounts of peanut protein through the skin, allowing the immune system to become desensitized to the allergen over time. This process aims to reduce the severity of allergic reactions to peanuts.
Approved indications
- Treatment of peanut allergy
Common side effects
- Skin irritation
- Itching
- Redness
- Swelling
- Hives
- Anaphylaxis
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Viaskin Peanut 250µg CI brief — competitive landscape report
- Viaskin Peanut 250µg updates RSS · CI watch RSS
- DBV Technologies portfolio CI